A5068113825- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Pharmaceutical studies and practices
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Hematopoietic Stem Cell Transplantation
- Bone and Joint Diseases
- COVID-19 and healthcare impacts
- Respiratory Support and Mechanisms
- Palliative Care and End-of-Life Issues
- Orthopedic Infections and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Family Support in Illness
- HIV/AIDS drug development and treatment
- COVID-19 Clinical Research Studies
- Pharmacogenetics and Drug Metabolism
- Advances in Oncology and Radiotherapy
- Adolescent and Pediatric Healthcare
- Neuroblastoma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Drug-Induced Hepatotoxicity and Protection
- Virus-based gene therapy research
Erasmus MC - Sophia Children’s Hospital
2020-2025
Princess Máxima Center
2019-2025
Erasmus University Rotterdam
2020-2023
Erasmus MC
2019-2023
University of Milano-Bicocca
2013-2022
Azienda Ospedaliera San Gerardo
2017-2019
Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1-18 years, R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m2. Using single-stage design, an overall response rate (ORR) ≤ 30% defined as not promissing and ORR > 55% expected, 25 patients needed be recruited achieve 80% power 0.05 significance level. Thirty-two enrolled, 28 treated, 27...
Inotuzumab ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin. The phase IB of the ITCC-059 trial tested InO combined chemotherapy in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Relapsed /refractory CD22+ BCP-ALL patients were enrolled. primary objective was to establish recommended II dose (RP2D). Secondary objectives included preliminary efficacy and tolerability. 1.5 mg/m2 vincristine (days 3, 10, 17, 24), 20 dexamethasone (2 5-day blocks,...
High-dose methotrexate (HD-MTX) infusions are commonly used to consolidate remission in children with acute lymphoblastic leukemia (ALL). We investigate the potential role of candidate polymorphisms SLCO1B1 (rs4149056 and rs2306283), ABCB1 (rs1045642), ABCC2 (rs717620), ABCC3 (rs9895420), ABCC4 (rs7317112) drug transporters genes on HD-MTX pharmacokinetics patients' outcome (meant both as relapse drug-related toxicities) an Italian cohort 204 ALL pediatric patients treated according...
Background Five Asociación de Hemato‐Oncología Centroamérica (AHOPCA) countries have used an adapted BFM‐based protocol for childhood acute lymphoblastic leukemia (ALL). Procedure In the AHOPCA‐ALL 2008 protocol, patients were stratified by age, white blood cell count, immunophenotype, central nervous system involvement, day 8 prednisone response, and morphologic bone marrow response to induction therapy. Patients at Standard Risk (SR) received a three‐drug regimen, reinduction phase,...
PurposeThe current standard-of-care for front-line therapy acute myeloid leukaemia (AML) is a combination of an anthracycline with cytarabine resulting in significant short-term and long-term toxicity, but still approximately 40% children relapse. Therefore, there major need to accelerate the introduction innovative medicines into therapy, yet drug development continues be adult-focused. Furthermore, are differences, including differing profiles genetic abnormalities, making clinical adult...
There is an increasing interest for anaplastic lymphoma kinase (ALK) inhibitors in pediatric oncology specific entities such as ALK-driven inflammatory myofibroblastic tumor (IMT). IMT treatment can be challenging due to localization of the and rare cases metastasis. When standard surgical not feasible, ALK may play important role, recently reported first-generation (crizotinib). However, data on second-generation are limited. We report two emblematic patients, treated with inhibitor...
Summary No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected internationally infants/young children (<3 years) with ALL treated InO. Fifteen patients (median 4.4 months at diagnosis) received InO due relapsed or refractory (R/R) disease. Median percentage of CD22 + blasts was 72% (range 40–100%, n = 9). The median dose the first course 1.74 mg/m 2 (fractionated). Seven (47%) achieved complete remission; one...
Bosutinib is approved for adults with chronic myeloid leukemia (CML): 400 mg once daily in newly diagnosed (ND); 500 resistant/intolerant (R/I) patients. has a different tolerability profile than other tyrosine kinase inhibitors (TKIs) and potentially less impact on growth (preclinical data). The primary objective of this first-in-child trial was to determine the recommended phase II dose (RP2D) pediatric R/I ND
Inotuzumab ozogamicin is an antibody-drug conjugate approved for treating relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in adults. Pediatric pharmacokinetic data of inotuzumab are lacking. This study the first to examine population pharmacokinetics pediatric patients with BCP-ALL.
Italy is the second exposed Country worldwide, after China, and Lombardia most affected Region in Italy, with more than half of National cases, 13% whom being healthcare professionals.The Clinica Pediatrica Università degli Studi di Milano Bicocca a General Pediatric Hematology Oncology Transplant Center embedded within designated COVID-19 general Hospital San Gerardo Monza, located Lombardia, Italy. Preventive control measures specifically undertaken to cope emergency Hemato-Oncology,...
Summary Osteonecrosis (ON) is a well‐known sequela of paediatric acute lymphoblastic leukaemia (ALL) treatment. Incidence differs substantially among studies and the clinical significance radiological findings not fully established. We analysed 256 consecutive patients with ALL treated in our Institution between October 2010 December 2016. Within cohort, 41 developed ON, mean 5‐year cumulative incidence 18.5 (standard error, SE, 5.7)% overall. The (SE) ON was 12.7 (2.1)% after censoring upon...
Isavuconazole is a new azole approved for adults with invasive aspergillosis and mucormycosis, favorable hepatic tolerability reported in Phase III trials. Here, we report on case of drug-induced liver failure related to isavuconazole pediatric patient treated after bone marrow transplant.
10017 Background: Bosutinib is a tyrosine kinase inhibitor (TKI), approved for adults with Philadelphia Chromosome (Ph+) CML; at the standard initial dose of 400 mg/day in ND patients, and 500 resistant/intolerant (R/I) administered orally once daily (QD) food. Compared to TKIs already pediatrics, bosutinib has different tolerability profile, preclinical data suggest that longitudinal growth potentially less impaired. Study NCT04258943 an international, open-label, phase I/II trial,...